Cyclerion Therapeutics (CYCN)
(Delayed Data from NSDQ)
$2.93 USD
-0.22 (-6.98%)
Updated Aug 30, 2024 09:30 AM ET
After-Market: $3.19 +0.26 (8.87%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
CYCN 2.93 -0.22(-6.98%)
Will CYCN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CYCN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CYCN
Cyclerion Therapeutics, Inc. (CYCN) Reports Q2 Loss, Misses Revenue Estimates
CYCN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CYCN
Cyclerion Therapeutics names Regina Graul as CEO
Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Therapeutics Appoints New CEO Regina Graul
Cyclerion Therapeutics appoints Regina Graul as CEO
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session